Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.47 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222627 | 0.91 | CTSK (0.46) | NOD1CTSKCTSSITGB3ITGA2B | |
| SCHEMBL7065541 | 0.91 | CTSK (0.46) | NOD1CTSKCTSSITGB3ITGA2B | |
| SCHEMBL2074961 | 0.86 | CTSK (0.50) | NOD1CTSKCTSS | |
| SCHEMBL5279118 | 0.86 | CTSK (0.50) | NOD1CTSKCTSS | |
| SCHEMBL3629433 | 0.84 | NOD1 (0.53) | NOD1SIRT2SIRT1SLC6A5 | |
| SCHEMBL4364211 | 0.83 | CTSK (0.45) | CTSKCTSSITGB3ITGA2B | |
| SCHEMBL1161276 | 0.83 | CTSK (0.45) | CTSKCTSSITGB3ITGA2B | |
| SCHEMBL22804102 | 0.83 | MEN1 (0.53) | CTSKSIRT2SIRT1CTSS | |
| SCHEMBL22804100 | 0.83 | MEN1 (0.53) | CTSKSIRT2SIRT1CTSS | |
| SCHEMBL3625936 | 0.83 | NOD1 (0.50) | NOD1SIRT2SIRT1SLC6A5ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799803-B2 | Hydroxamic acid compounds and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-09-21 | — | — | US | disclosed |
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-7199134-B2 | Hydroxamic acid compounds and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | HDAC5, BRDT, HDAC1 | NOD1 3525/4885CTSK 1702/4885SIRT2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.